Medication info
Actosmet Tablets 15/850 mg (Pioglitazone Hydrochloride, Metformin Hydrochloride)

Actosmet Tablets 15/850 mg (Pioglitazone Hydrochloride, Metformin Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Celltrion Pharmaceutical Co., Ltd.
Appearance
White to grayish-white, oblong, convex film-coated tablets
Packaging
Blister - 28 tablets/Alu-Alu[(7 X 4ea)], Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Approval status
Active

MFDS item code 202500638 · Approved 2025.03.20 · Insurance code 693903990

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine once daily, and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their previous doses of pioglitazone and metformin. 3. Patients with renal impairment: All dosage adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this medicine. After administering this medicine to a patient or increasing the dose, monitor carefully for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Ingredients

Manufacturer
Celltrion Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication is designed to assist patients with type 2 diabetes in controlling their blood sugar levels. It works in conjunction with dietary and exercise regimens, using a combination of pioglitazone and metformin to effectively lower and manage blood sugar. This enables stable management of blood sugar levels, contributing to the prevention of complications. Thus, using this medication as part of a systematic treatment plan can be very helpful in blood sugar control.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine once daily, and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their previous doses of pioglitazone and metformin. 3. Patients with renal impairment: All dosage adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this medicine. After administering this medicine to a patient or increasing the dose, monitor carefully for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Precautions

This medication helps regulate blood sugar levels for patients with type 2 diabetes, and the two components work together to lower blood sugar. When taking this medication, it is essential to confirm that kidney function is normal, as it is safest not to use it if kidney function is impaired. Patients with abnormal liver function or liver disease should consult a physician before taking this medication and should undergo regular liver function tests. Patients with heart disease or heart failure need to be cautious when using this medication, and especially those with severe heart failure should not start taking it. This medication can cause a rare but serious side effect known as lactic acidosis, so if symptoms such as malaise, muscle pain, difficulty breathing, or abdominal pain occur, it is crucial to inform a doctor immediately. Alcohol consumption may increase the risk of side effects from this medication, so excessive drinking should be avoided while taking it. Women who are pregnant or may become pregnant, as well as breastfeeding women, are advised not to take this medication. During treatment with this medication, regular checks of blood sugar, kidney function, liver function, and hematological tests should be conducted to monitor for any abnormalities. There may be interactions with other drugs, so anyone taking other medications should inform their doctor or pharmacist, especially if taking drugs that could affect kidney function. In case of overdose, it is crucial to visit a medical facility for appropriate treatment, and if necessary, dialysis may be performed to remove the medication. This medication has not been proven safe and effective for children, so it is not used in pediatric patients. Elderly patients are likely to have reduced kidney function, so initial and maintenance doses should be determined with caution, and kidney function should be frequently evaluated. Weight gain, edema, and symptoms of heart failure may occur during treatment with this medication, so it is important to consult healthcare providers if these symptoms arise. While taking this medication, it is important to maintain regular meals and exercise and to continually monitor blood sugar control.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • asthenia
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 40 more
  • congestive heart failure
  • excessive and rapid weight change
  • dyspnea
  • edema
  • upper respiratory infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • elevated ALT
  • elevated CPK
  • decreased vision
  • diabetic macular edema
  • liver failure
  • edema
  • fluid retention
  • volume-related cases
  • gross hematuria
  • urinary disorders
  • urgency
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intestinal aeropathy
  • increased serum creatinine
  • increased blood urea
  • fractures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Ideally, it should be stored at room temperature, between 1 degree and 30 degrees.

Appearance and packaging

Appearance

White to grayish-white, oblong, convex film-coated tablets

Package unit

Blister - 28 tablets/Alu-Alu[(7 X 4ea)], Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.